All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Novartis trades in flat to Bunds, Swiss retail clamour for rare AAA corporate

Novartis, the Swiss pharmaceutical company, demonstrated its pulling power to investors this week by issuing a Eu1bn 3.75% five year bond at 16bp over the Bobl, or 11bp through mid-swaps — levels that would be the envy of triple-A issuers such as KfW and the EIB.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree